Academic Journal
An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)
| العنوان: | An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial) |
|---|---|
| المؤلفون: | Sach, T H, Thomas, K S, Batchelor, J M, Perways, A, Chalmers, J R, Haines, R H, Meakin, G D, Duley, L, Ravenscroft, J C, Rogers, A, Santer, M, Tan, W, White, J, Whitton, M E, Williams, H C, Cheung, S T, Hamad, H, Wright, A, Ingram, J R, Levell, N, Goulding, J M R, Makrygeorgou, A, Bewley, A, Ogboli, M, Stainforth, J, Ferguson, A, Laguda, B, Wahie, S, Ellis, R, Azad, J, Rajasekaran, A, Eleftheriadou, V, Montgomery, A A |
| سنة النشر: | 2021 |
| المجموعة: | University of Southampton: e-Prints Soton |
| الوصف: | Background: Economic evidence for vitiligo treatments is absent. Objectives: To determine the cost-effectiveness of (i) handheld narrowband ultraviolet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-UVB compared with TCS alone for localized vitiligo. Methods: Cost-effectiveness analysis alongside a pragmatic, three-arm, placebo-controlled randomized controlled trial with 9 months’ treatment. In total 517 adults and children (aged ≥ 5 years) with active vitiligo affecting < 10% of skin were recruited from secondary care and the community and were randomized 1: 1: 1 to receive TCS, NB-UVB or both. Cost per successful treatment (measured on the Vitiligo Noticeability Scale) was estimated. Secondary cost–utility analyses measured quality-adjusted life-years using the EuroQol 5 Dimensions 5 Levels for those aged ≥ 11 years and the Child Health Utility 9D for those aged 5 to < 18 years. The trial was registered with number ISRCTN17160087 on 8 January 2015. Results: The mean ± SD cost per participant was £775 ± 83·7 for NB-UVB, £813 ± 111.4 for combination treatment and £600 ± 96·2 for TCS. In analyses adjusted for age and target patch location, the incremental difference in cost for combination treatment compared with TCS was £211 (95% confidence interval 188–235), corresponding to a risk difference of 10·9% (number needed to treat = 9). The incremental cost was £1932 per successful treatment. The incremental difference in cost for NB-UVB compared with TCS was £173 (95% confidence interval 151–196), with a risk difference of 5·2% (number needed to treat = 19). The incremental cost was £3336 per successful treatment. Conclusions: Combination treatment, compared with TCS alone, has a lower incremental cost per additional successful treatment than NB-UVB only. Combination treatment would be considered cost-effective if decision makers are willing to pay £1932 per additional treatment success. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| Relation: | https://eprints.soton.ac.uk/444660/1/bjd.19554.pdf; Sach, T H, Thomas, K S, Batchelor, J M, Perways, A, Rogers, A, Santer, M, Tan, W, Whitton, M E, Williams, H C, Wright, A, Ingram, J R and Ferguson, A , UK Dermatology Clinical Trials Network’s HI-LIGHT Vitiligo Trial Team (2021) An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial). British Journal of Dermatology, 184 (5), 840-848. (doi:10.1111/bjd.19554 ). |
| الاتاحة: | https://eprints.soton.ac.uk/444660/ https://eprints.soton.ac.uk/444660/1/bjd.19554.pdf |
| Rights: | accepted_manuscript |
| رقم الانضمام: | edsbas.789B3DFF |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |